Rising Biosciences Announces
Official Sales and Distribution of its RSB0238 Clinical Strength
Peptide Complex on Amazon
RSII's serum ranks
among top best-sellers in its
category
Sandusky, OH
-- May 01,
2018 -- InvestorsHub NewsWire --
Rising India, Inc.'s Rising Biosciences (OTC:RSII)
("RSII" "the
Company"), a research and
development company focusing on oral and topical pharmaceuticals
with strict standards set forward by the pharmaceutical compounding
industry, is pleased to announce that Amazon
is now officially stocking and fulfilling orders via Amazon
distribution centers throughout the USA for the Company's
revolutionary RSB0238 Clinical Strength Peptide Complex.
(product
link:
https://www.amazon.com/dp/B07CJKTZ2M/ref=cm_sw_r_other_apa_mi31Ab5X0TMAY)
Amazon Prime
members receive free two day shipping on the serum, which debuted
to 5-star reviews and ranked among the best-selling new
releases in the facial serum category.
COO
Arthur Hall commented: "This
is the first of
many RSII products that we'll
be offering via Amazon
distribution centers throughout the United States
with
all order
fulfillment performed
directly by
Amazon. RSII has achieved a
highly desirable
relationship here, and
one we
intend to
further cultivate. I hope
that it is clear to all that this is a monumental achievement for
RSII that I believe will propel RSII to the next level of
growth. That being
said, We
are also
working with a broker to establish a presence in nationally
recognized brick and mortar stores throughout the
country."
Rising
Biosciences team is thrilled to announce that their
next
product moving
into production
is
its RBS0346
Clinical Strength Stem Cell Cream.
Hall
comments, "It's safe to say that the
anti-aging skin care market is not slowing down anytime soon. The
global skin care industry is estimated to reach $131 billion in
2019 and we intend to capture an impactful market share as we
continue to innovate and deliver products with unparalleled
effect."
"Rising Biosciences Inc. along
with PAO Group Inc. helping reduce the grip of
opiods on America through the responsible
use of cannabis"
$RSII on
Twitter for LIVE company updates! www.twitter.com/risingindiausa
Forward-Looking Statements:
Certain statements in this news release may contain forward-looking
information within the meaning of Rule 175 under the Securities Act
of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934,
and are subject to the safe harbor created by those rules. All
statements, other than statements of fact, included in this
release, including, without limitation, statements regarding
potential future plans and objectives of the company, are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications, which may arise, could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The Company undertakes no duty to revise or update any
forward- looking statements to reflect events or circumstances
after the date of this release.
CONTACT
INFO:
For Investor
Inquiries:
IR@risingbiosciences.com
